Dacarbazine - Dacarbazine is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Dacarbazine is used to treat skin cancer (malignant melanoma) and Hodgkin\'s disease.
Dacarbazine may also be used for purposes not listed in this medication guide.
Pharmacology: Exact mechanism is unknown. Three mechanisms are hypothesized: 1) inhibition of DNA synthesis by acting as a purine analog; 2) action as an alkylating agent; and 3) interaction with sulfhydryl groups.
Indication: Treatment of metastatic malignant melanoma; in combination with other agents as second-line therapy for Hodgkin disease.
In combination with cyclophosphamide and vincristine for malignant pheochromocytoma; in combination with other agents for treatment of advanced metastatic soft tissue sarcoma; alone or in combination with other agents for management of Kaposi sarcoma.
Dacarbazine is a synthetic analog of naturally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide (AIC). After intravenous administration of dacarbazine, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations Dacarbazine is not appreciably bound to human plasma protein.
Intravenous Metastatic melanoma
Adult: 2-4.5 mg/kg daily for 10 days, repeat at 4-wk intervals or 200-250 mg/m 2 BSA daily for 5 days, repeat at 3-wk intervals or 850 mg/m 2 BSA by infusion, repeat at 3-wk intervals. Intravenous Hodgkin\'s disease
Adult: 150 mg/m 2 BSA daily for 5 days, repeat every 4 wk or 375 mg/m 2 BSA every 15 days in combination with other agents. Intravenous Soft tissue sarcoma
Adult: 250 mg/m 2 BSA daily for 5 days repeated every 3 wk. Usually given with doxorubicin. Incompatibility: Incompatible with hydrocortisone sodium succinate, L-cysteine, sodium hydrogen carbonate and concentrated heparin (25 mg/ml).
Adult: IV Metastatic melanoma 2-4.5 mg/kg/day for 10 days, repeat at 4-wkly intervals. Hodgkin\'s disease 150 mg/m 2 /day for 5 days, repeat at 4-wkly intervals. Soft tissue sarcoma 250 mg/m 2 /day for 5 days, repeat at 3-wkly intervals.